{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/pruritus-vulvae/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"38dfa294-fe36-5eaf-801f-f85edcaf9b0c","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 425a95b5-367a-4359-9040-b3f9ea43738e --><h2>Changes</h2><!-- end field 425a95b5-367a-4359-9040-b3f9ea43738e -->","summary":null,"htmlStringContent":"<!-- begin item ecc73ef7-769d-4103-87f8-1030c2d3dc65 --><!-- begin field 7cad6185-287d-42b3-bc7a-20f887e6c04a --><p><strong>May to June 2017</strong> — reviewed. A literature search was conducted in May 2017 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. </p><!-- end field 7cad6185-287d-42b3-bc7a-20f887e6c04a --><!-- end item ecc73ef7-769d-4103-87f8-1030c2d3dc65 -->","topic":{"id":"ab775596-ee36-566c-b99e-f26281476587","topicId":"f736b71a-0394-4d1b-81d3-89f92387f7b5","topicName":"Pruritus vulvae","slug":"pruritus-vulvae","lastRevised":"Last revised in May 2017","chapters":[{"id":"e95d24eb-aeb8-50bb-ac51-8f64aea3c30a","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"8ce4dbd7-2246-5775-ae6e-04329c1190c1","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"982a2f05-e887-58b7-b162-572ce0d3ee9f","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"38dfa294-fe36-5eaf-801f-f85edcaf9b0c","slug":"changes","fullItemName":"Changes"},{"id":"3ad7e907-7bc6-5339-9fe3-a53a943a1d5b","slug":"update","fullItemName":"Update"}]},{"id":"cfeab3a1-33f8-5401-bf2d-554006509e44","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f358fbd3-3112-597d-8318-782024ffb462","slug":"goals","fullItemName":"Goals"},{"id":"06d9f87d-ffb9-5c80-94cc-c14fabec72e4","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"00abbaa1-76de-5699-92e4-c7966d120fb9","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8c5bcf9e-40a1-5ec5-bfb3-8b61c5e05271","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"9e5947c9-06ae-527b-b39d-99249cc183b7","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"acce3106-835f-51e5-8d2a-474eb1210f06","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"ede3d467-474d-5337-a3a8-69e962cdb78d","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"fed1d461-c450-5ad2-b137-ba2e7b3e25ba","slug":"definition","fullItemName":"Definition"},{"id":"69ac7b79-9272-52fb-b41a-85c62d368278","slug":"causes","fullItemName":"Causes"},{"id":"540240f7-7b5f-5dd8-9778-add2bad7a948","slug":"prevalence","fullItemName":"Prevalence"},{"id":"f32fb44d-4398-544d-8e12-40abce15c8ac","slug":"prognosis","fullItemName":"Prognosis"},{"id":"d3481fe5-fb32-5604-a01e-ef3831740641","slug":"complications","fullItemName":"Complications"}]},{"id":"ea7b6574-3e2d-5558-b3fc-e26e23ee9841","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"cb8a05d1-5735-53f1-9f3d-a8eeeaf04c43","slug":"assessment","fullItemName":"Assessment"},{"id":"d9fb23e4-f170-5e35-baf1-eb5e9eb3ef93","slug":"causes","fullItemName":"Causes"},{"id":"b2f116aa-c92b-555e-bf3d-4d48002ac082","slug":"investigations","fullItemName":"Investigations"}]},{"id":"33ec4dfa-a698-5c63-ba2b-63ff2bd4f94a","fullItemName":"Management","slug":"management","subChapters":[{"id":"39b5f2b6-2faf-5764-932b-10c3cfa35b9c","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"879b4dcf-9fd5-5785-ad0a-f78ce4711c69","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"40a71a96-802a-52ed-936a-8be2564e3966","slug":"topical-corticosteroids","fullItemName":"Topical corticosteroids"},{"id":"5a7e3fc5-3dcc-5ae7-b42c-cfd50c0b6427","slug":"hydroxyzine","fullItemName":"Hydroxyzine"}]},{"id":"e8fd8512-18b4-5a87-b393-c17a7aeea18c","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"22929cbe-97bb-51fd-848d-fb564e84e824","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"16e021f3-7a43-5db6-91c6-f2928df8f0d3","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"1e67be49-3ad9-5c49-afd7-3b4003a9e1ac","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"aa214653-3cef-5171-bc52-2abc1dca4efe","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"9f82fff6-ebda-5cfb-8995-424680c23073","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"3a44b88d-e6de-5027-a2a5-aab8d22fae10","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"2255e17a-9ac2-5004-9c32-22c36192790a","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"982a2f05-e887-58b7-b162-572ce0d3ee9f","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"b6bd8687-30d0-5039-a6bc-5077c09f9ee2","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field fc3990d2-dcd8-4aa6-9a42-c1a42cda36c3 --><h3>Previous changes</h3><!-- end field fc3990d2-dcd8-4aa6-9a42-c1a42cda36c3 -->","summary":null,"htmlStringContent":"<!-- begin item 39ed3f9f-1f2c-4829-9225-043bc883566c --><!-- begin field a7fb0f96-ca96-446d-a2e6-31f5976cc323 --><p><strong>May 2016 </strong>— minor update. Text updated to reflect the Medicines and Healthcare products Regulatory Agency (MHRA) safety update on the risk of QT interval prolongation and Torsade de Pointes with hydroxyzine.</p><p><strong>December 2013 </strong>— minor update. A link to the NICE guidance on urinary incontinence has been replaced with a link to the CKS topic on <em>Incontinence - urinary, in women</em>.</p><p><strong>May 2013 </strong>— minor update. The prescriptions for aqueous cream have been removed following advice issued by the MHRA regarding aqueous cream and the higher risk of skin irritation.</p><p><strong>June 2011 </strong>— references updated due to an RCOG partial update. No changes made to the CKS topic. Issued in June 2011.</p><p><strong>November 2010 to February 2011 </strong>— topic updated. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. There are no major changes to the recommendations.</p><p><strong>October 2010 </strong>— minor update. Generic chlorphenamine is no longer licensed for the treatment of pruritus. Text and prescriptions amended to reflect this. Issued in October 2010.</p><p><strong>December 2006 to March 2007 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. There are no major changes to the recommendations.</p><p><strong>July 2005 </strong>— updated to incorporate the <em>Referral guidelines for suspected cancer </em>published by the National Institute for Health and Clinical Excellence. Issued in July 2005.</p><p><strong>April 2002 </strong>— reviewed. Validated in June 2002 and issued in July 2002.</p><p><strong>July 1999 </strong>— written, replacing guidance called <em>Pruritus vulvae/pruritus of genital organs</em>. Validated in October 1999 and issued in January 2000.</p><!-- end field a7fb0f96-ca96-446d-a2e6-31f5976cc323 --><!-- end item 39ed3f9f-1f2c-4829-9225-043bc883566c -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}